

10TH SPRING MEETING REDUX
VIRTUAL

MARCH 15-17, 2021

Viral Vectors & Vaccines

Chaired By:

María Mercedes Segura, PhD

AVROBIO

Lawrence C. Thompson, PhD

Pfizer, Inc.

Otto-Wilhelm Merten, PhD

Miltenyi Biotec Inc.

Cellular Therapies

Chaired By:

Martin A. Giedlin, PhD

PACT pharma

Baculovirus Expression Technology

Chaired By:

Dominic Esposito, PhD

Frederick National Laboratory for Cancer Research

António M. Roldão, PhD

Instituto de Biologia Experimental e Tecnológica (iBET)

MONDAY - MARCH 15, 2021

9:00 am – 9:15 am

Intro/Overview

9:15 am – 9:30 am

Break

Viral Vectors & Vaccines

Cellular Therapies

Baculovirus Expression Technology

9:30 am – 10:10 am

Functional Roles of the Novel AAV Membrane-Associated Accessory Protein

Lionel Galibert, PhD

Kuopio Center for Gene and Cell Therapy

Autologous Cell Therapy Manufacturing Innovation and Industry 4.0 Solutions

Ohad Karnieli, PhD

AdvaBio Ltd.

BacMam-Mediated In Situ Modification of Recombinant ACE2 Extracellular Domain

Christopher W. Kemp, PhD

Kemp Proteins, LLC

10:10 am – 10:25 am

Break

10:25 am – 11:05 am

Commercial Readiness for Gene Therapy Analytics

Vesselin Mitaksov

Pfizer, Inc.

Recommendations for the Development of Allogeneic CAR T-Cell Products — A CBER Perspective

Tal Salz, PhD

FDA CBER

Screening and Production of Human Proteins Using Baculovirus and BacMam

Nicola A. Burgess-Brown, PhD

University of Oxford

11:05 am – 11:20 am

Break

All of the presentations shown in the program are included with your registration fee.
Times are Eastern Daylight Time (EDT). Eastern Standard Time (EST) switches to EDT on Sunday, March 14th.

The ISBioTech 10th Spring Meeting Redux (continued): MONDAY • MARCH 15, 2021

11:20 am – 11:50 am	Technology Workshop <i>Goldilocks and the Three Cells: The Art of Monitoring & Managing Cell Cultures</i> Beckman Coulter Life Sciences	Technology Workshop <i>How to Mitigate Contamination Risk for Viral Vector Large-Scale Production</i> Pall Biotech	Technology Workshop <i>Considerations for Plasmid DNA in Gene Therapy: Evaluating the Impact of How Materials are Used on Design, Characterization, and Specifications</i> Aldevron
11:50 am – 12:40 pm	Lunch		
12:40 pm – 1:10 pm	Technology Workshop <i>Protein or Not? Advanced High-Throughput Aggregate Analysis with the Aura</i> Halo Labs	Technology Workshop <i>Scaling Up Viral Vector and Vaccine Manufacturing with the VHU®</i> Artemis Biosystems	Technology Workshop <i>HumanKine FGF Basic — A Case Study</i> Proteintech Group, Inc
1:10 pm – 1:25 pm	Break		
	Viral Vectors & Vaccines	Cellular Therapies	Baculovirus Expression Technology
1:25 pm – 2:05 pm	<i>Scale-Up of rAAV Production Using Stable Producer Cell Lines</i> Juliana Coronel, PhD Cevec Pharmaceuticals GmbH	<i>Automation in Delivery Technologies to Empower Breakthrough Therapies</i> Anil Narasimha, PhD Mekonos	<i>Baculovirus-Cell Interactions in the Insect Midgut: Transcriptome Profiling and Envelope Protein Trafficking</i> Gary W. Blissard, PhD Boyce Thompson Institute
2:05 pm – 2:20 pm	Break		
2:20 pm – 3:00 pm	<i>Development and Validation of a Potency Assay for a Viral-Based Gene Therapy Product</i> Rashmi Prasad, PhD MassBiologics	<i>Spearheading a Paradigm Shift in Cell Therapy Manufacturing</i> Fabian Gerlinghaus Cellares Inc.	<i>Process Intensification for a Human Recombinant Influenza Vaccine</i> Nikolai Khramtsov, PhD Protein Sciences Corporation, A Sanofi Company
3:00 pm – 3:15 pm	Break		
3:15 pm – 4:00 pm	Lentiviral Vector Reference Material Project Update		

TUESDAY • MARCH 16, 2021

9:00 am – 9:15 am	Intro/Overview
9:15 am – 9:30 am	Break

All of the presentations shown in the program are included with your registration fee.
Times are Eastern Daylight Time (EDT). Eastern Standard Time (EST) switches to EDT on Sunday, March 14th.

	Viral Vectors & Vaccines	Cellular Therapies	Baculovirus Expression Technology
9:30 am – 10:10 am	<i>R&D and Process Development Activities for the Continuous Optimization of Lentiviral Vectors</i> Juan Carlos Ramirez, PhD VIVEbiotech	<i>Considerations for the Development of Gene-Edited Stem Cell Therapies</i> Brent Morse Vor Biopharma	<i>Multiple Recombinant Protein Expression in Insect Cells: Fundamental and Applied Outcomes</i> Polly Roy, PhD London School of Hygiene & Tropical Medicine
10:10 am – 10:25 am	Break		
10:25 am – 11:05 am	<i>Developing a Potency Assay for a Proprietary AAV-Based Genome Editing Platform Technology</i> Matthias Hebben, PhD LogicBio Therapeutics	<i>New Nanotechnology for Efficient Non-Viral Gene Delivery to Cells Ex Vivo</i> Christopher Ballas, PhD Innovative Cellular Therapeutics Co., Ltd.	<i>Development of Mayaro Virus and SARS-CoV-2 Virus-Like Particle Vaccines from Insect Cells</i> Sandra R. Abbo and Linda van Oosten Wageningen University
11:05 am – 11:20 am	Break		
11:20 am – 11:50 am	Technology Workshop <i>Videodrop, a New Tool for Measuring Size and Concentration of Nanoparticles in 40s in a Single Drop</i> Myriade	Technology Workshop <i>Quantification of Viral and Non-Viral Vector CQAs</i> Wyatt Technology Corporation	Technology Workshop <i>Chromatographic Tools for the Optimization of IVT Reaction and mRNA Purification Process Improvement</i> BIA Separations, a Sartorius company
11:50 am – 12:40 pm	Lunch		
	Viral Vectors & Vaccines	Cellular Therapies	Baculovirus Expression Technology
12:40 pm – 1:20 pm	<i>Routine Size, Mass, Aggregate Level, Total Concentration, and Full-Empty Ratio Determinations by SEC-MALS</i> Darren W. Begley, PhD Beam Therapeutics	<i>Building Effective Control Strategies for Cellular Therapy and Other Complex Biopharmaceutical Products</i> Mark F. Witcher, PhD Exyte	<i>Advances in Bioprocessing and Analytics to Accelerate Influenza VLP-Based Vaccine Development</i> Ricardo Correia Instituto de Biologia Experimental e Tecnológica (iBET)
1:20 pm – 1:35 pm	Break		
1:35 pm – 2:15 pm	<i>Accelerating Cell and Gene Therapy Clinical Pipelines and Path to Commercialization with a Robust Lentiviral Vector Platform and a Scalable Manufacturing Process</i> Kevin Beck, PhD Lentigen Technology Inc., a Miltenyi Biotec Company	<i>Enhancing Cryopreservation Outcome through Molecular and Device-Based Strategies</i> John M. Baust PhD CPSI Biotech	<i>Baculovirus-Sf9 System for the Manufacture of NVX-CoV2373 Vaccine</i> Gale E. Smith, PhD Novavax, Inc.
2:15 pm – 2:30 pm	Break		
2:30 pm – 3:00 pm	Technology Workshop <i>On the Importance of Monitoring Both Transfection and Transduction Efficiencies in Cell Therapy Development</i> Beckman Coulter Life Sciences	Technology Workshop <i>Design, Manufacturing, and Analytics of New AAV Reference Standards — A Case Study</i> Vigene Biosciences	Technology Workshop <i>Properties and Applications of Sf-RVN®, an Sf-Rhabdovirus-Negative Sf Cell Line</i> GlycoBac LLC
3:00 pm – 3:15 pm	Break		
3:15 pm – 3:45 pm	Technology Workshop <i>Scalable, High-Titer Production of Adeno-Associated Virus in the Gibco™ AAV-MAX Helper-Free AAV Production System</i> Thermo Fisher Scientific		

All of the presentations shown in the program are included with your registration fee.
Times are Eastern Daylight Time (EDT). Eastern Standard Time (EST) switches to EDT on Sunday, March 14th.

9:00 am – 9:15 am	Intro/Overview		
9:15 am – 9:30 am	Break		
9:30 am – 10:00 am	Technology Workshop <i>Next-Generation Transfection Reagent for Large-Scale AAV Manufacturing</i> Polyplus-transfection SA	Technology Workshop <i>TheraPEAK SfAAV Medium, the Next Step in AAV Production</i> Lonza	Technology Workshop <i>ExpiSf™: A Versatile Chemically-Defined Sf9/Baculovirus Expression System</i> Thermo Fisher Scientific
10:00 am – 10:15 am	Break		
10:15 am – 10:45 am	Technology Workshop <i>AAV Manufacturing Platform and In-Process Controls</i> BIA Separations, a Sartorius company	Technology Workshop <i>TransIT-VirusGEN GMP: An Innovative Transfection Platform for Cell and Gene Therapy Development and Manufacture</i> Mirus Bio LLC	Technology Workshop <i>The Role of Technology Innovation in Bridging the Gap in Viral Vector Manufacturing Capacity for Gene Therapy Availability</i> Univercells Technologies
10:45 am – 11:00 am	Break		
	Viral Vectors & Vaccines	Cellular Therapies	Baculovirus Expression Technology
11:00 am – 11:40 am	<i>rVSV-Vectored Vaccine Production in Vero Cells</i> Sascha Kiesslich, PhD McGill University	<i>Optimizing Cell Manufacturing Processes for the Treatment of Severe Genetic Diseases and Cancer</i> Elizabeth Pratico, PhD bluebird bio Inc.	<i>Baculovirus-Based Vaccines for Rift Valley Fever Virus</i> Jürgen A. Richt, DVM, PhD Kansas State University
11:40 am – 12:30 pm	Lunch		
12:30 pm – 1:10 pm	<i>Advances in Lentiviral Vector Production Leading to Improved Purity and Potency</i> Nicholas Clarkson, PhD Oxford BioMedica plc	<i>Machine Learning Applications for the Characterization of Particle Profiles of Therapeutic Products</i> Amber H. Fradkin, PhD KBI Biopharma	<i>Viral Vector Production Using the Baculovirus-Insect Cell Expression System: AAV Case Study</i> Pranavkumar Joshi, PhD McGill University
1:10 pm – 1:25 pm	Break		
1:25 pm – 2:05 pm	<i>AAV Vector and Manufacturing Process Design Considerations: A 2021 Perspective</i> John Fraser Wright, PhD Stanford University	<i>Advanced Therapies, Clinical Holds, and Strategies to Avoid</i> Debra A. Webster, PhD BlueRock Therapeutics	<i>Ongoing Work for Expression of Difficult-to-Express Proteins and Protein Complexes</i> Yuichiro Takagi, PhD Indiana University School of Medicine
2:05 pm – 2:20 pm	Break		
2:20 pm – 3:00 pm	<i>Development of a GMP Relevant Process for Gene Circuit Engineered Allogeneic CAR-NK Cell Therapies in Oncology</i> Philip Lee, PhD Senti Biosciences	<i>New Technologies for Robust and Efficient Large-Scale Production of Recombinant Multi-Protein Complexes</i> Jill O. Fuss, PhD Lawrence Berkeley National Laboratory	
3:00 pm – 3:15 pm	Break		
3:15 pm – 4:15 pm	Roundtable		

All of the presentations shown in the program are included with your registration fee.

Times are Eastern Daylight Time (EDT). Eastern Standard Time (EST) switches to EDT on Sunday, March 14th.

Due to circumstances beyond the control of meeting organizers, this program is subject to change without notice. REV 03/15/2021